AMGEN INC Revenue (ASC 606)

Quick Answer

AMGEN INC reported Revenue (ASC 606) of $36.75 billion for fiscal year 2025.

AMGEN INC Revenue (ASC 606) — Annual History

Fiscal Year Revenue (ASC 606) YoY Change
2025 $36.75B +10.0%
2024 $33.42B +18.6%
2023 $28.19B +7.1%
2022 $26.32B +1.3%
2021 $25.98B +2.2%
2020 $25.42B +8.8%
2019 $23.36B

Quarterly Revenue (ASC 606)

Quarter Ending Revenue (ASC 606) YoY QoQ
September 30, 2025 $9.56B +12.4% +4.1%
June 30, 2025 $9.18B +9.4% +12.6%
March 31, 2025 $8.15B +9.4% -4.2%
September 30, 2024 $8.50B +23.2% +1.4%
June 30, 2024 $8.39B +20.1% +12.6%
March 31, 2024 $7.45B +22.0% +7.9%
September 30, 2023 $6.90B +3.8% -1.2%
June 30, 2023 $6.99B +5.9% +14.4%
  • AMGEN INC showed an increase of +10.0% in Revenue (ASC 606) compared to the prior fiscal year.
  • Over the 2019–2025 period, AMGEN INC’s revenue (asc 606) has grown by 57.3% (from $23.36 billion to $36.75 billion).
  • The most recent figure is from AMGEN INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 13, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment